56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation Leflunomide protective? Have others seen this? #ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv

This study evaluated effectiveness of SEC in PsA prevention of a subgroup of pts from SELENA: PsO pts w/o PsA & nail dse (n=292) At 5 yrs: 🎯98.3% didn't develop PsA (yEAIR 0.49) 🎯 Sustained PASI, PGA 0/1 💡Longterm SEC effective for PsA prevention? #ACR25 @RheumNow Abs1463 https://t.co/t7P1Oerbrw

12 year follow up radiographic data in axial SpA - ASAS definition of early stage does not significantly influence long term radiographic outcomes. Abt#1432 #ACR25 @RheumNow https://t.co/fFP2CW6X0B

Survival outcomes in patients with axial SpA and concomitant cancer are the same as those without. #abst1429 #ACR25 @RheumNow https://t.co/wicN3s9JrR

Sun et al. Telitacicept in SARD-ILD (pSS, ASS, RA). 25 patients. Improvements in CT, PFTs, 6MWT. @RheumNow #ACR25 Abstr#1361 https://t.co/q679LOaOyL

Short chain fatty acids (SCFA) and the relevant microbiome have been linked to RA development and severity. Study of monozygotic twins, where only one has RA, two diff cohorts: lower SCFA lower SCFA microbiome Biomarkers, or even therapeutic target? #ACR25 ABST0442 @RheumNow https://t.co/HW1YfkfOG3

Classification of sacrioilitis using new york criteria vs a convolutional neural network. Abst#1421 #acr25 @RheumNow Yes no results - accuracy was 70 percent. But the exact grade was right 22 percent times only! https://t.co/9o8OGesH0n

Global survey from the 2024 Adelphi Lupus Dse Specific Programme evaluated pt burden & MD/Pt Tx preferences: Efficacy & safety - top 2 MD-reported reasons for tx initiation OD, oral dosing-most preferred mode by MD & Pts Shared decision-making is key #ACR25 @RheumNow Abs1551 https://t.co/rmpCATCa78

In pooled analysis of 9 PsA trials, 6.9% of secukinumab-treated patients had fungal infections, mostly mild/moderate. Candida rates were low (1.86–2.18/100 PY) and didn’t increase over time. 89.7% resolved fully; only 0.8% led to discontinuation. Abstract 1459 @RheumNow #ACR25 https://t.co/kltMZVEDf9

Screening for ILD in RA patients: CXR and PFTs by themselves are close to a waste of time. When it comes to screening (high-risk) RA patients, it’s HRCT (or lung USS) or nothing really. (in keeping with EULAR, ACR guidelines) #ACR25 ABST1335 @RheumNow https://t.co/XBDxLwYsAT

England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta